March 12, 2018 Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
February 22, 2018 Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
February 22, 2018 New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
February 14, 2018 UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
February 14, 2018 Sienna Biopharmaceuticals announces First Patient Dosed in First-In-Human Trial of Topical SNA-125
February 5, 2018 Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
January 23, 2018 UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option
January 18, 2018 Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
January 16, 2018 Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
January 8, 2018 UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
December 11, 2017 Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
December 10, 2017 Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
November 29, 2017 Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
November 15, 2017 Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy
November 6, 2017 UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
November 2, 2017 UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors
October 26, 2017 UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs
October 24, 2017 Sienna Biopharmaceuticals announces First Patient Dosed In Phase 2B Trial of Topical SNA-120
October 18, 2017 Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
October 6, 2017 Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
October 4, 2017 Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
